Skip to content
2000
image of Exploring the Therapeutic Potential of Crisaborole Gel in Atopic Dermatitis: A Review

Abstract

Atopic Dermatitis (AD) is a long-lasting, inflammatory, and itchy skin disease related to asthma, hay fever, and a family history of the condition. It is the most common chronic skin disease in children, affecting 18% of 7-year-olds. The prevalence of AD in children in the United States is 17.2%, which is comparable to that in Europe and Japan. Greater socioeconomic groupings, fewer families, and metropolitan areas all have higher AD prevalence rates. It is thought that a mix of environmental and genetic factors produces the condition. The gene that codes for the skin matrix protein filaggrin is the most strongly linked genetic link currently identified with AD. Increased water loss due to AD-induced breakdown of the skin barrier leads to dry skin, heightening vulnerability to microbial colonization, allergy sensitization, and infection. PDE4, an intracellular enzyme present in inflammatory cells, is greater in persons with active AD and latent allergic rhinitis. Consequently, crisaborole, a PDE4 inhibitor, raises intracellular cAMP levels, activating Protein Kinase A (PKA), suggesting potential therapeutic options for the dysregulated inflammatory cycle associated with this disease. Thus, Crisaborole should be regarded as the safest and most effective option for treating atopic dermatitis. Crisaborole's specific mechanism, safety profile, and effectiveness in interrupting the inflammatory cycle make it an attractive treatment alternative, according to this study. Crisaborole is presented here as a potential remedy to address the research gap: the need for safer, more efficient therapies that target inflammatory pathways in AD.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raddf/10.2174/0126673878342969251128064804
2026-01-22
2026-02-03

  • From This Site

    /content/journals/raddf/10.2174/0126673878342969251128064804
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Chiesa Fuxench Z.C. Atopic dermatitis: Disease background and risk factors. Adv. Exp. Med. Biol. 2017 1027 11 19 10.1007/978‑3‑319‑64804‑0_2
    [Google Scholar]
  2. Beattie P.E. Lewis-Jones M.S. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br. J. Dermatol. 2006 155 1 145 151 10.1111/j.1365‑2133.2006.07185.x 16792766
    [Google Scholar]
  3. Williams H.C. Epidemiology of atopic dermatitis. Clin. Exp. Dermatol. 2000 25 7 522 529 10.1046/j.1365‑2230.2000.00698.x 11122223
    [Google Scholar]
  4. Eyerich K. Novak N. Immunology of atopic eczema: Overcoming the Th1/Th2 paradigm. Allergy 2013 68 8 974 982 10.1111/all.12184 23889510
    [Google Scholar]
  5. Nahid S. Saeedi S. Hopkins C.R. Phosphodiesterase 4 (PDE4) and neurological disorders: A promising frontier in neuropharmacology. Adv. Pharmacol. 2025 102 159 209 10.1016/bs.apha.2024.10.005 39929579
    [Google Scholar]
  6. Lowe A.J. Carlin J.B. Bennett C.M. Do boys do the atopic march while girls dawdle? J. Allergy Clin. Immunol. 2008 121 5 1190 1195 10.1016/j.jaci.2008.01.034 18313134
    [Google Scholar]
  7. Thestruppedersen K. The incidence and pathophysiology of atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 1996 7 Suppl. S3 S7 10.1016/0926‑9959(96)00033‑5
    [Google Scholar]
  8. Gupta D. Atopic dermatitis. Med. Clin. North Am. 2015 99 6 1269 1285 10.1016/j.mcna.2015.07.006 26476252
    [Google Scholar]
  9. Weidinger S. Novak N. Atopic dermatitis. Lancet 2016 387 10023 1109 1122 10.1016/S0140‑6736(15)00149‑X 26377142
    [Google Scholar]
  10. Sroka-Tomaszewska J. Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int. J. Mol. Sci. 2021 22 8 4130 10.3390/ijms22084130 33923629
    [Google Scholar]
  11. Guttman-Yassky E. Diaz A. Pavel A.B. Use of tape strips to detect immune and barrier abnormalities in the skin of children with early-onset atopic dermatitis. JAMA Dermatol. 2019 155 12 1358 1370 10.1001/jamadermatol.2019.2983 31596431
    [Google Scholar]
  12. dos Santos J.C. Azor M.H. Nojima V.Y. Increased circulating pro-inflammatory cytokines and imbalanced regulatory T-cell cyto-kines production in chronic idiopathic urticaria. Int. Immunopharmacol. 2008 8 10 1433 1440 10.1016/j.intimp.2008.05.016 18586117
    [Google Scholar]
  13. Pellefigues C. IgE autoreactivity in atopic dermatitis: Paving the road for autoimmune diseases? Antibodies 2020 9 3 47 10.3390/antib9030047 32911788
    [Google Scholar]
  14. Deo S. Mistry K. Kakade A. Niphadkar P. Role played by Th2 type cytokines in IgE mediated allergy and asthma. Lung India 2010 27 2 66 71 10.4103/0970‑2113.63609 20616938
    [Google Scholar]
  15. Laughter D. Istvan J.A. Tofte S.J. Hanifin J.M. The prevalence of atopic dermatitis in Oregon schoolchildren. J. Am. Acad. Dermatol. 2000 43 4 649 655 10.1067/mjd.2000.107773 11004621
    [Google Scholar]
  16. Larsen F.S. Diepgen T. Svensson Å. The occurrence of atopic dermatitis in North Europe: An international questionnaire study. J. Am. Acad. Dermatol. 1996 34 5 760 764 10.1016/S0190‑9622(96)90009‑2 8632070
    [Google Scholar]
  17. Sugiura H. Umemoto N. Deguchi H. Prevalence of childhood and adolescent atopic dermatitis in a Japanese population: Compari-son with the disease frequency examined 20 years ago. Acta Derm. Venereol. 1998 78 4 293 294 10.1080/000155598441891 9689299
    [Google Scholar]
  18. Schultz Larsen F. Hanifin J.M. Secular change in the occurrence of atopic dermatitis. Acta Derm. Venereol. Suppl. 1992 176 7 121476042
    [Google Scholar]
  19. Eichenfield L.F. Hanifin J.M. Beck L.A. Atopic dermatitis and asthma: Parallels in the evolution of treatment. Pediatrics 2003 111 3 608 616 10.1542/peds.111.3.608 12612244
    [Google Scholar]
  20. Williams H.C. Strachan D.P. The natural history of childhood eczema: Observations from the British 1958 birth cohort study. Br. J. Dermatol. 1998 139 5 834 839 10.1046/j.1365‑2133.1998.02509.x 9892950
    [Google Scholar]
  21. Wüthrich B. Clinical aspects, epidemiology, and prognosis of atopic dermatitis. Ann. Allergy Asthma Immunol. 1999 83 5 464 470 10.1016/S1081‑1206(10)62852‑9 10582732
    [Google Scholar]
  22. Nutten S. Atopic dermatitis: Global epidemiology and risk factors. Ann. Nutr. Metab. 2015 66 Suppl. 1 8 16 10.1159/000370220 25925336
    [Google Scholar]
  23. Barnes K.C. An update on the genetics of atopic dermatitis: Scratching the surface in 2009. J. Allergy Clin. Immunol. 2010 125 1 16 29.e11 10.1016/j.jaci.2009.11.008 20109730
    [Google Scholar]
  24. Boguniewicz M. Leung D.Y.M. Atopic dermatitis: A disease of altered skin barrier and immune dysregulation. Immunol. Rev. 2011 242 1 233 246 10.1111/j.1600‑065X.2011.01027.x 21682749
    [Google Scholar]
  25. Leung D.Y.M. New insights into atopic dermatitis: Role of skin barrier and immune dysregulation. Allergol. Int. 2013 62 2 151 161 10.2332/allergolint.13‑RAI‑0564 23712284
    [Google Scholar]
  26. Guttman-Yassky E. Nograles K.E. Krueger J.G. Contrasting pathogenesis of atopic dermatitis and psoriasis—Part I: Clinical and patholog-ic concepts. J. Allergy Clin. Immunol. 2011 127 5 1110 1118 10.1016/j.jaci.2011.01.053 21388665
    [Google Scholar]
  27. Bunikowski R. Mielke M. Skarabis H. Prevalence and role of serum IgE antibodies to the StaphylococcuS aureus–derived superan-tigens SEA and SEB in children with atopic dermatitis. J. Allergy Clin. Immunol. 1999 103 1 119 124 10.1016/S0091‑6749(99)70535‑X 9893195
    [Google Scholar]
  28. Salt B.H. Boguniewicz M. Leung D.Y.M. Severe refractory atopic dermatitis in adults is highly atopic. J. Allergy Clin. Immunol. 2007 119 2 508 509 10.1016/j.jaci.2006.11.006 17194471
    [Google Scholar]
  29. Gupta J. Grube E. Ericksen M.B. Intrinsically defective skin barrier function in children with atopic dermatitis correlates with dis-ease severity. J. Allergy Clin. Immunol. 2008 121 3 725 730.e2 10.1016/j.jaci.2007.12.1161 18249438
    [Google Scholar]
  30. Grewe S.R. Chan S.C. Hanifin J.M. Elevated leukocyte cyclic AMP—phosphodiesterase in atopic disease: A possible mechanism for cyclic AMP—agonist hyporesponsiveness. J. Allergy Clin. Immunol. 1982 70 6 452 457 10.1016/0091‑6749(82)90008‑2 6128357
    [Google Scholar]
  31. Bäumer W. Hoppmann J. Rundfeldt C. Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm. Allergy Drug Targets 2007 6 1 17 26 10.2174/187152807780077318 17352685
    [Google Scholar]
  32. Novak N. Bieber T. Leung D.Y.M. Immune mechanisms leading to atopic dermatitis. J. Allergy Clin. Immunol. 2003 112 6 S128 S139 10.1016/j.jaci.2003.09.032 14657843
    [Google Scholar]
  33. Essayan D.M. Huang S.K. Kagey-Sobotka A. Lichtenstein L.M. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J. Allergy Clin. Immunol. 1997 99 1 28 37 10.1016/S0091‑6749(97)81041‑X 9003208
    [Google Scholar]
  34. Essayan D.M. Huang S.K. Undem B.J. Kagey-Sobotka A. Lichtenstein L.M. Modulation of antigen- and mitogen-induced proliferative re-sponses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J. Immunol. 1994 153 8 3408 3416 10.4049/jimmunol.153.8.3408 7930566
    [Google Scholar]
  35. Dastidar S.G. Rajagopal D. Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr. Opin. Investig. Drugs 2007 8 5 364 372 10.1007/978‑3‑642‑17969‑3_17 17520865
    [Google Scholar]
  36. Jimenez J.L. Punzón C. Navarro J. Muñoz-Fernández M.A. Fresno M. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J. Pharmacol. Exp. Ther. 2001 299 2 753 759 10.1016/S0022‑3565(24)29287‑9 11602691
    [Google Scholar]
  37. Torphy T.J. Phosphodiesterase isozymes. Am. J. Respir. Crit. Care Med. 1998 157 2 351 370 10.1164/ajrccm.157.2.9708012 9476844
    [Google Scholar]
  38. Giembycz M.A. Phosphodiesterase 4 and tolerance to β2-adrenoceptor agonists in asthma. Trends Pharmacol. Sci. 1996 17 9 331 336 10.1016/0165‑6147(96)10039‑0 8885699
    [Google Scholar]
  39. Gonzalez G.A. Montminy M.R. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 1989 59 4 675 680 10.1016/0092‑8674(89)90013‑5 2573431
    [Google Scholar]
  40. Wen A.Y. Sakamoto K.M. Miller L.S. The role of the transcription factor CREB in immune function. J. Immunol. 2010 185 11 6413 6419 10.4049/jimmunol.1001829 21084670
    [Google Scholar]
  41. Hou S. Guan H. Ricciardi R.P. Phosphorylation of serine 337 of NF-kappaB p50 is critical for DNA binding. J. Biol. Chem. 2003 278 46 45994 45998 10.1074/jbc.M307971200 12947093
    [Google Scholar]
  42. Kwak H.J. Song J.S. Heo J.Y. Yang S.D. Nam J.Y. Cheon H.G. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J. Pharmacol. Exp. Ther. 2005 315 3 1188 1195 10.1124/jpet.105.092056 16126838
    [Google Scholar]
  43. Chow C.W. Davis R.J. Integration of calcium and cyclic AMP signaling pathways by 14-3-3. Mol. Cell. Biol. 2000 20 2 702 712 10.1128/MCB.20.2.702‑712.2000 10611249
    [Google Scholar]
  44. Stork P.J.S. Dillon T.J. Multiple roles of Rap1 in hematopoietic cells: Complementary versus antagonistic functions. Blood 2005 106 9 2952 2961 10.1182/blood‑2005‑03‑1062 16076873
    [Google Scholar]
  45. Mosenden R. Taskén K. Cyclic AMP-mediated immune regulation - Overview of mechanisms of action in T cells. Cell. Signal. 2011 23 6 1009 1016 10.1016/j.cellsig.2010.11.018 21130867
    [Google Scholar]
  46. Thomsen S.F. Ulrik C.S. Kyvik K.O. Importance of genetic factors in the etiology of atopic dermatitis: A twin study. Allergy Asthma Proc. 2007 28 5 535 539 10.2500/aap2007.28.3041 18034971
    [Google Scholar]
  47. Hachisuka J. Takeuchi S. Kido M. Fukiwake N. Furue M. Severity of disease, rather than xerosis, correlates with pruritus in patients with atopic dermatitis. Int. J. Dermatol. 2009 48 4 374 378 10.1111/j.1365‑4632.2009.03906.x 19335422
    [Google Scholar]
  48. Palmer C.N.A. Irvine A.D. Terron-Kwiatkowski A. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 2006 38 4 441 446 10.1038/ng1767 16550169
    [Google Scholar]
  49. De Benedetto A. Kubo A. Beck L.A. Skin barrier disruption: A requirement for allergen sensitization? J. Invest. Dermatol. 2012 132 3 949 963 10.1038/jid.2011.435 22217737
    [Google Scholar]
  50. Williams H.C. Jburney P.G. Hay R.J. The U.K. Working party’s diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br. J. Dermatol. 1994 131 3 383 396 10.1111/j.1365‑2133.1994.tb08530.x 7918015
    [Google Scholar]
  51. NICE clinical guidelines. 2007 Available from: www.ncc-wch.org.uk
  52. Sheehan-Dare R.A. Henderson M.J. Cotterill J.A. Anxiety and depression in patients with chronic urticaria and generalized pruritus. Br. J. Dermatol. 1990 123 6 769 774 10.1111/j.1365‑2133.1990.tb04195.x 2265093
    [Google Scholar]
  53. Halvorsen J.A. Lien L. Dalgard F. Bjertness E. Stern R.S. Suicidal ideation, mental health problems, and social function in adolescents with eczema: A population-based study. J. Invest. Dermatol. 2014 134 7 1847 1854 10.1038/jid.2014.70 24496238
    [Google Scholar]
  54. Carroll C.L. Balkrishnan R. Feldman S.R. Fleischer A.B. Manuel J.C. The burden of atopic dermatitis: Impact on the patient, family, and society. Pediatr. Dermatol. 2005 22 3 192 199 10.1111/j.1525‑1470.2005.22303.x 15916563
    [Google Scholar]
  55. Schut C. Bosbach S. Gieler U. Kupfer J. Personality traits, depression and itch in patients with atopic dermatitis in an experimental set-ting: A regression analysis. Acta Derm. Venereol. 2014 94 1 20 25 10.2340/00015555‑1634 23756579
    [Google Scholar]
  56. Dieris-Hirche J. Gieler U. Kupfer J.P. Milch W.E. Suicidal ideation, anxiety and depression in adult patients with atopic dermatitis. Hautarzt 2009 60 8 641 646 10.1007/s00105‑009‑1744‑y 19399379
    [Google Scholar]
  57. Simpson E.L. Comorbidity in atopic dermatitis. Curr. Dermatol. Rep. 2012 1 1 29 38 10.1007/s13671‑011‑0003‑5 23745171
    [Google Scholar]
  58. Kimata H. Prevalence of suicidal ideation in patients with atopic dermatitis. Suicide Life Threat. Behav. 2006 36 1 120 124 10.1521/suli.2006.36.1.120 16676633
    [Google Scholar]
  59. Dalgard F.J. Gieler U. Tomas-Aragones L. The psychological burden of skin diseases: A cross-sectional multicenter study among dermatological out-patients in 13 European countries. J. Invest. Dermatol. 2015 135 4 984 991 10.1038/jid.2014.530 25521458
    [Google Scholar]
  60. Noh H.M. Cho J.J. Park Y.S. Kim J.H. The relationship between suicidal behaviors and atopic dermatitis in Korean adolescents. J. Health Psychol. 2016 21 10 2183 2194 10.1177/1359105315572453 25736391
    [Google Scholar]
  61. Mina S. Jabeen M. Singh S. Verma R. Gender differences in depression and anxiety among atopic dermatitis patients. Indian J. Dermatol. 2015 60 2 211 10.4103/0019‑5154.152564 25814727
    [Google Scholar]
  62. Picardi A. Lega I. Tarolla E. Suicide risk in skin disorders. Clin. Dermatol. 2013 31 1 47 56 10.1016/j.clindermatol.2011.11.006 23245973
    [Google Scholar]
  63. Lewis-Jones S. Quality of life and childhood atopic dermatitis: The misery of living with childhood eczema. Int. J. Clin. Pract. 2006 60 8 984 992 10.1111/j.1742‑1241.2006.01047.x 16893440
    [Google Scholar]
  64. Ponte L.G. Ebert U. Frontiers of rapid itch relief: A review of methylprednisolone aceponate. J. Eur. Acad. Dermatol. Venereol. 2012 26 s6 9 13 10.1111/j.1468‑3083.2012.04711.x 23067432
    [Google Scholar]
  65. Spergel J.M. Paller A.S. Atopic dermatitis and the atopic march. J. Allergy Clin. Immunol. 2003 112 6 S118 S127 10.1016/j.jaci.2003.09.033 14657842
    [Google Scholar]
  66. Harvey J Lax SJ Lowe A The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review. Skin Health Dis 2023 3 5 ski2.268 10.1002/ski2.268 37799373
    [Google Scholar]
  67. Schneider L. Tilles S. Lio P. Atopic dermatitis: A practice parameter update 2012. J. Allergy Clin. Immunol. 2013 131 2 295 299 10.1016/j.jaci.2012.12.672 23374261
    [Google Scholar]
  68. Lio P.A. Non-pharmacologic therapies for atopic dermatitis. Curr. Allergy Asthma Rep. 2013 13 5 528 538 10.1007/s11882‑013‑0371‑y 23881511
    [Google Scholar]
  69. Callen J. Chamlin S. Eichenfield L.F. A systematic review of the safety of topical therapies for atopic dermatitis. Br. J. Dermatol. 2007 156 2 203 221 10.1111/j.1365‑2133.2006.07538.x 17223859
    [Google Scholar]
  70. Rathi S.K. D’Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J. Dermatol. 2012 57 4 251 259 10.4103/0019‑5154.97655 22837556
    [Google Scholar]
  71. Arellano F.M. Wentworth C.E. Arana A. Fernández C. Paul C.F. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J. Invest. Dermatol. 2007 127 4 808 816 10.1038/sj.jid.5700622 17096020
    [Google Scholar]
  72. Nnoruka E.N. Daramola O.O.M. Ike S.O. Misuse and abuse of topical steroids: Implications. Expert. Rev. Dermatol. 2007 2 1 31 40 10.1586/17469872.2.1.31
    [Google Scholar]
  73. Kragballe K. Topical corticosteroids: Mechanisms of action. Acta Derm. Venereol. Suppl. 1989 151 7 10 10.1016/S0733‑8635(18)30044‑5 2533778
    [Google Scholar]
  74. Akers W.A. Risks of unoccluded topical steroids in clinical trials. Arch. Dermatol. 1980 116 7 786 788 10.1001/archderm.1980.01640310056019 6994659
    [Google Scholar]
  75. Hajar T. Leshem Y.A. Hanifin J.M. A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J. Am. Acad. Dermatol. 2015 72 3 541 549.e2 10.1016/j.jaad.2014.11.024 25592622
    [Google Scholar]
  76. Smith S.D. Hong E. Fearns S. Blaszczynski A. Fischer G. Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups. Australas. J. Dermatol. 2010 51 3 168 174 10.1111/j.1440‑0960.2010.00636.x 20695854
    [Google Scholar]
  77. Arellano F.M. Arana A. Wentworth C.E. Fernández-Vidaurre C. Schlienger R.G. Conde E. Lymphoma among patients with atopic dermati-tis and/or treated with topical immunosuppressants in the United Kingdom. J. Allergy Clin. Immunol. 2009 123 5 1111 1116 10.1016/j.jaci.2009.02.028 19361841
    [Google Scholar]
  78. Margolis D.J. Abuabara K. Hoffstad O.J. Wan J. Raimondo D. Bilker W.B. Association between malignancy and topical use of pimecroli-mus. JAMA Dermatol. 2015 151 6 594 599 10.1001/jamadermatol.2014.4305 25692459
    [Google Scholar]
  79. Luger T. Boguniewicz M. Carr W. Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatr. Allergy Immunol. 2015 26 4 306 315 10.1111/pai.12331 25557211
    [Google Scholar]
  80. Ring J. Möhrenschlager M. Henkel V. The US FDA ‘black box’ warning for topical calcineurin inhibitors: An ongoing controversy. Drug Saf. 2008 31 3 185 198 10.2165/00002018‑200831030‑00001 18302444
    [Google Scholar]
  81. Diaz A. Guttman-Yassky E. Topical agents for the treatment of atopic dermatitis. Expert Rev. Clin. Immunol. 2019 15 4 369 382 10.1080/1744666X.2019.1564038 30587053
    [Google Scholar]
  82. Crisaborole. 2015 Available from: https://pubchem.ncbi.nlm. nih.gov/compound/906673-24-3
  83. Akama T. Baker S.J. Zhang Y.K. Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg. Med. Chem. Lett. 2009 19 8 2129 2132 10.1016/j.bmcl.2009.03.007 19303290
    [Google Scholar]
  84. Nazarian R. Weinberg J.M. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr. Opin. Investig. Drugs 2009 10 11 1236 1242 [PMID: 19876791
    [Google Scholar]
  85. Freund Y.R. Akama T. Alley M.R.K. Boron‐based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal cen-ter. FEBS Lett. 2012 586 19 3410 3414 10.1016/j.febslet.2012.07.058 22841723
    [Google Scholar]
  86. Zane L.T. Chanda S. Jarnagin K. Nelson D.B. Spelman L. Gold L.F.S. Crisaborole and its potential role in treating atopic dermatitis: Over-view of early clinical studies. Immunotherapy 2016 8 8 853 866 10.2217/imt‑2016‑0023 27283509
    [Google Scholar]
  87. Jarnagin K. Chanda S. Coronado D. Crisaborole topical ointment, 2%: A nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J. Drugs Dermatol. 2016 15 4 390 396 [PMID: 27050693
    [Google Scholar]
  88. Zane L.T. Kircik L. Call R. Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: A phase 1b, open-label, maximal-use systemic exposure study. Pediatr. Dermatol. 2016 33 4 380 387 10.1111/pde.12872 27193740
    [Google Scholar]
  89. Zane L.T. Hughes M.H. Shakib S. Tolerability of crisaborole ointment for application on sensitive skin areas: A randomized, double-blind, vehicle-controlled study in healthy volunteers. Am. J. Clin. Dermatol. 2016 17 5 519 526 10.1007/s40257‑016‑0204‑6 27335049
    [Google Scholar]
  90. McDowell L. Olin B. Crisaborole: A novel nonsteroidal topical treatment for atopic dermatitis. J. Pharm. Technol. 2019 35 4 172 178 10.1177/8755122519844507 34861031
    [Google Scholar]
  91. Alomar A. Berth-Jones J. Bos J.D. The role of topical calcineurin inhibitors in atopic dermatitis. Br. J. Dermatol. 2004 151 s70 3 27 10.1111/j.1365‑2133.2004.06269.x 15548171
    [Google Scholar]
  92. study of crisaborole ointment 2% in children aged 3-24 months with mild to moderate atopic dermatitis 2018 NCT03356977. Available from: https://clinicaltrials.gov/ct2/show/NCT03356977
  93. Stein Gold L.F. Spelman L. Spellman M.C. Hughes M.H. Zane L.T. A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J. Drugs Dermatol. 2015 14 12 1394 1399 [PMID: 26659931
    [Google Scholar]
  94. Tom W.L. Van Syoc M. Chanda S. Zane L.T. Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in ado-lescents with atopic dermatitis: An open-label phase 2a study. Pediatr. Dermatol. 2016 33 2 150 159 10.1111/pde.12780 26777394
    [Google Scholar]
  95. Murrell D.F. Gebauer K. Spelman L. Zane L.T. Crisaborole topical ointment, 2% in adults with atopic dermatitis: A phase 2a, vehicle-controlled, proof-of-concept study. J. Drugs Dermatol. 2015 14 10 1108 1112 [PMID: 26461821
    [Google Scholar]
  96. Paller A.S. Tom W.L. Lebwohl M.G. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J. Am. Acad. Dermatol. 2016 75 3 494 503.e6 10.1016/j.jaad.2016.05.046 27417017
    [Google Scholar]
  97. Eichenfield L.F. Call R.S. Forsha D.W. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J. Am. Acad. Dermatol. 2017 77 4 641 649.e5 10.1016/j.jaad.2017.06.010 28823881
    [Google Scholar]
  98. Yosipovitch G. Gold L. Lebwohl M. Silverberg J. Tallman A. Zane L. Early relief of pruritus in atopic dermatitis with crisaborole oint-ment, a non-steroidal, phosphodiesterase 4 inhibitor. Acta Derm. Venereol. 2018 98 5 484 489 10.2340/00015555‑2893 29363715
    [Google Scholar]
/content/journals/raddf/10.2174/0126673878342969251128064804
Loading
Exploring the Therapeutic Potential of Crisaborole Gel in Atopic Dermatitis: A Review
Bentham Science Publishers ; https://doi.org/10.2174/0126673878342969251128064804
/content/journals/raddf/10.2174/0126673878342969251128064804
/content/journals/raddf/10.2174/0126673878342969251128064804
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: pruritus ; filaggrin gene mutation ; chronic skin disease ; phosphodiesterase 4 inhibitors ; allergic sensitization ; Atopic dermatitis ; pediatric dermatology

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test